Perceptronix Medical Inc. (PMI) is a privately owned and cancer diagnostics company specializing in the provision of early cancer detection tests based on quantitative cytology platform. The Company has the distribution and collection kits for sale based on quantitative cytology imaging analysis (ClearCyte™) including staining kit (Clear2C™) for use in hospitals, universities and commercial laboratories.
PMI’s intellectual property which forms the bases of its automated platforms was developed and licensed from BC Cancer Agency in Vancouver. PMI Tech works with partner laboratories around the world to improve the detection and diagnosis of various types of cancer.
Since incorporation, in 1999, PMI has successfully built an ISO 9001:2000 and ISO 13485:2003 certified quality management system, received Health Canada and EU approval for its technology.